PK/PD Modeling

Take advantage of our extensive experience in modeling PK and pharmacokinetics / pharmacodynamics (PK/PD) to more fully understand the expected therapeutic behavior of your compounds in vivo. We can predict activities in multiple organs in human or pre-clinical species for a wide range of pre-clinical or clinical scenarios.

If you are uncertain, feel free to use our service selector to learn more about the service most suitable for you.

• Use pre-clinical PK, ADME and efficacy data to understand pre-clinical PD and predict human PD.
• Rigorous model development process
• Off-the-shelf models and bespoke modeling service available
• Model complex PK and PD scenarios:
  • Prodrug/drug/metabolite PK
  • Multi-drug therapies
  • Therapeutic outcomes in blood or extra-vascular tissues.
• Expert result interpretation, reporting and advice

• Plasma, blood or tissue concentration data from one or more pre-clinical species, and in vitro ADME data for the corresponding species
• Corresponding in vitro ADME data for human
• Drug activity data – whether measured in vitro and/or in vivo
• Compound structure – as either SDF or SMILES file

The process is an interactive one between the client and experts in Cyprotex’s Modeling and Simulation Group. Projects typically start with an assessment of the client’s in vitro and in vivo data, followed by discussion of the most appropriate modeling approaches that can be taken. Model development and assessment is conducted with progress updates and discussion with the client. The interval and nature of the feedback process is at the discretion of the client, as is the final reporting format.

Precise details of the results to be returned are dependent upon the objectives of the client, and are usually specified before the start of each project. They will typically include:

• Assessment of the data provided by the client
• Details of model development process undertaken
• Details, including parameter values, of any models used or produced during the projects
• Results of modeling inter-species scaling and extrapolations to human or other species, where relevant.
• Comparison of models, wherever more than one model is involved
• Determination of PK drivers of efficacy, where relevant.
• Predictions of PK and PD for one or more dosing regimens to be selected by the client, in human or other species.

The nature of the deliverables to be generated are usually specified before the start of each project, and will typically comprise one or more of the following:

• Presentations with slide sets typically in Microsoft PowerPoint.
• Prose reports, typically in Microsoft Word.

Files (e.g. csv or Microsoft Excel) containing predicted plasma/blood/tissue concentrations and/or calculated PK parameters in human for dosing regimens selected by the client.

PK/PD modeling refers to the integration of pharmacokinetic and pharmacodynamic model components into a single model that enables prediction of the time course of effect intensity in response to administration of a drug regimen.

Cyprotex Modelling and Simulation staff will work with you to combine your specific domain expertise with our extensive experience in PK and PD model development, to generate robust PK/PD models. You can use these models to inform your subsequent discovery and development strategies, such as compound progression, further experimental prioritization and design, and human dose selection.